^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MFSD2A overexpression

    i
    Other names: MFSD2A, MFSD2 Lysolipid Transporter A, Lysophospholipid, Sodium-Dependent Lysophosphatidylcholine Symporter 1, Major Facilitator Superfamily Domain Containing 2A, Sodium-Dependent LPC Symporter 1, SLC59A1, MFSD2, Major Facilitator Superfamily Domain-Containing Protein 2A, FLJ14490, HsMFSD2A, NLS1, Major Facilitator Superfamily Domain Containing 2, NEDMISBA, MCPH15, MFSD2a
    Entrez ID:
    84879
    over2years
    MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response. (PubMed, Cancer Commun (Lond))
    MFSD2A potentially serves as a predictive biomarker for anti-PD-1 immunotherapy response in AGC patients. MFSD2A may be a promising therapeutic target to potentiate the efficacy of anti-PD-1 immunotherapy by reprogramming the TME to promote T cells activation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1) • MFSD2A (MFSD2 Lysolipid Transporter A)
    |
    MFSD2A overexpression